Core Points - The company DaBo Medical announced that its shareholder DaBo International reduced its stake by 1.968 million shares through block trading on October 31, 2025, accounting for 0.48% of the total share capital [1] - Before the reduction, DaBo International held 82.9269 million shares, representing 20.03% of the total shares; after the reduction, its holdings decreased to 80.9589 million shares, reducing its stake to 19.55% [1] - The combined shareholding ratio of DaBo International and its concerted parties decreased from 84.24% to 83.77%, reaching a 1% integer threshold [1] - This reduction aligns with the previously disclosed plan, and the reduction plan has not yet been fully implemented [1]

证券代码：002901 证券简称：大博医疗 公告编号：2025-049 大博医疗科技股份有限公司 关于持股 5%以上股东减持股份触及 1%整数倍的公告 股东大博医疗国际投资有限公司保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 董事会 大博医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日披露 了《关于持股 5%以上股东股份减持计划的预披露公告》（公告编号：2025-033）。 持有公司 82,926,901 股股份（占公司当前总股本 414,019,506 股的比例为 20.03%， 占剔除回购专户股份数量后公司总股本 406,609,606 股的比例为 20.39%）的股东 大博医疗国际投资有限公司（以下简称"大博国际"）计划自本公告披露之日起 15 个交易日后的 3 个月内（即 2025 年 9 月 18 日至 2025 年 12 月 17 日，根据相 关法律法规禁止减持的期间除外）以集中竞价或大宗交易方式减持公司股份不超 过 8,280,390 ...

交易信息汇总资金流向 10月31日主力资金净流出14.64万元；游资资金净流入1253.59万元；散户资金净流出1238.94万元。 截至2025年10月31日收盘，大博医疗(002901)报收于50.04元，上涨1.38%，换手率1.58%，成交量4.55万 手，成交额2.28亿元。 当日关注点 10月31日大博医疗发生1笔大宗交易，成交金额9052.8万元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：10月31日大博医疗主力资金净流出14.64万元，游资资金净流入1253.59万元， 散户资金净流出1238.94万元。 来自交易信息汇总：10月31日大博医疗发生1笔大宗交易，成交金额9052.8万元。 大宗交易 ...

Core Viewpoint - The stock of Dabo Medical (002901) has shown a slight increase of 1.38% on October 31, 2025, closing at 50.04 yuan, with notable fluctuations in capital flow and strong financial performance in recent quarters [1][3]. Financial Performance - For the first three quarters of 2025, Dabo Medical reported a main revenue of 1.876 billion yuan, a year-on-year increase of 22.69% [3]. - The net profit attributable to shareholders reached 425 million yuan, up 77.03% year-on-year [3]. - The third quarter alone saw a main revenue of 666 million yuan, reflecting a 17.82% increase year-on-year, and a net profit of 180 million yuan, which is a 77.49% increase year-on-year [3]. Market Position - Dabo Medical's total market capitalization stands at 20.718 billion yuan, significantly higher than the industry average of 11.561 billion yuan, ranking 12th in the industry [3]. - The company has a gross margin of 71.23%, which is above the industry average of 51.22%, ranking 16th in the industry [3]. - The return on equity (ROE) is reported at 12.83%, substantially higher than the industry average of 0.15%, ranking 7th in the industry [3]. Capital Flow Analysis - On October 31, 2025, the net outflow of main funds was 146,400 yuan, accounting for 0.06% of the total transaction amount, while retail investors experienced a net outflow of 1.239 million yuan, representing 5.43% of the total transaction amount [1][2]. - Over the past five days, the stock has seen varying capital flows, with significant retail and speculative fund movements impacting the overall trading dynamics [2].

Core Viewpoint - A block trade of 1.968 million shares of Dabo Medical occurred on October 31, with a transaction value of 90.528 million yuan, at a price of 46.00 yuan per share, representing an 8.07% discount to the closing price of the day [1] Trading Activity - The closing price of Dabo Medical on October 31 was 50.04 yuan, reflecting a 1.38% increase, with a turnover rate of 1.58% and a total transaction volume of 228 million yuan [1] - The net inflow of main funds for the day was 3.6275 million yuan, while the stock has seen a cumulative decline of 5.26% over the past five days, with a total net outflow of 11.4 million yuan [1] Margin Financing - The latest margin financing balance for Dabo Medical is 162 million yuan, which has increased by 25.2645 million yuan over the past five days, marking an 18.51% increase [1] Company Background - Dabo Medical Technology Co., Ltd. was established on August 12, 2004, with a registered capital of 4.14019506 billion yuan [1]

Summary of Key Points Core Viewpoint - On October 31, 2023, a block trade for Dabo Medical occurred, with a total transaction volume of 1.968 million shares and a transaction value of 90.528 million yuan, indicating a discount of 8.07% compared to the closing price of the day [1]. Group 1: Transaction Details - The average transaction price was 46.00 yuan per share [1]. - The transaction was executed through CITIC Securities Co., Ltd. Xiamen Branch as both the buyer and seller [1]. - The total volume of shares traded was 1,968,000 shares [1]. Group 2: Financial Metrics - The total transaction amount reached 90.528 million yuan [1]. - The discount of 8.07% reflects a notable deviation from the market closing price, which may indicate investor sentiment or market conditions at the time of the trade [1].

Core Insights - Dabo Medical reported a revenue of 666 million yuan for Q3 2025, representing a year-on-year growth of 17.82% [2] - The company achieved a net profit attributable to shareholders of 180 million yuan, marking a significant year-on-year increase of 77.49% [2] Financial Performance - Revenue for Q3 2025: 666 million yuan, up 17.82% year-on-year [2] - Net profit attributable to shareholders for Q3 2025: 180 million yuan, up 77.49% year-on-year [2]

Core Viewpoint - On October 31, Dabo Medical experienced a block trade with a transaction price of 46 yuan, reflecting an 8.07% discount compared to the closing price of the same day [1] Group 1: Block Trade Details - The block trade involved 1.968 million shares, amounting to 90.528 million yuan [1] - The buyer and seller were both from the Xiamen branch of CITIC Securities Co., Ltd [1] - In the past three months, there has been one block trade for this stock, totaling 19,700 hands, with one transaction at a discount [1] Group 2: Stock Performance - As of October 31, 2025, Dabo Medical (002901) closed at 50.04 yuan, up 1.38% with a turnover rate of 1.58% [1] - The trading volume was 45,500 hands, with a total transaction value of 228 million yuan [1] - Recently, one institution has given a buy rating for the stock [1]

Core Insights - A new venture capital partnership named Xiamen Fuchuang Dabo Medical Industry Venture Capital Partnership (Limited Partnership) has been established with a capital contribution of 300 million RMB [1] Company Information - The executing partner of the newly formed partnership is Fujian Innovation and Entrepreneurship Investment Management Co., Ltd [1] - The partnership includes contributions from Fujian Investment Development Group Co., Ltd, Guangxi Dabo Shangtong Venture Capital Co., Ltd, Xiamen Haicang Industrial Development Equity Investment Partnership (Limited Partnership), and Fujian Innovation and Entrepreneurship Investment Management Co., Ltd [1] Investment Focus - The operational scope of the partnership is focused on venture capital investments [1]

Summary of Key Points Core Viewpoint - Dabo Medical (002901) experienced a significant decline in stock price, closing at 49.36 yuan on October 30, 2025, with a drop of 7.2% [1][2]. Trading Information - The stock has seen a continuous decline for two consecutive days, with a total drop of 9.73% over the last ten trading days [1][2]. - On October 30, the trading volume was 5.66 million shares, with a total transaction value of 285 million yuan [1]. - The main funds experienced a net outflow of 2,453.83 million yuan over the past ten trading days, while the financing balance decreased by 1,113.82 million yuan [1][2]. Fund Flow - On October 30, the main funds had a net outflow of 1,409.55 million yuan, while retail and speculative funds saw net inflows of 615.62 million yuan and 793.92 million yuan, respectively [1][2].